Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1B | Q00975 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.33 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.31 |
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
| ▸ | FLT3 | P36888 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.30 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12099616 | 0.82 | CACNA1B (0.38) | CACNA1BHSD11B1HCRTR1HCRTR2HTR2A | |
| SCHEMBL12099414 | 0.77 | HSD11B1 (0.46) | CACNA1BHSD11B1 | |
| SCHEMBL12100616 | 0.75 | METAP1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL1809430 | 0.67 | CACNA1B (0.50) | CACNA1BHSD11B1HTR2AHTR6KCNH2 | |
| SCHEMBL12099973 | 0.65 | PDE10A (0.36) | CACNA1BHTR6FLT3 | |
| SCHEMBL12100279 | 0.64 | ELOVL6 (0.38) | HTR6FLT3 | |
| SCHEMBL12100071 | 0.63 | SLC40A1 (0.48) | FLT3 | |
| SCHEMBL12100104 | 0.61 | ALDH1A1 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL1811520 | 0.60 | CACNA1B (0.50) | CACNA1BHSD11B1HTR2AHTR6KCNH2 | |
| SCHEMBL12099725 | 0.60 | SCN9A (0.39) | PIM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | RAQUALIA PHARMA INC. (JP) | 2012-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120232052-A1 | ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS | SCN1B, SCN1A, SCN2B | CACNA1B 17/4885HSD11B1 2985/4885SLC6A9 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.